AiCuris GmbH and Co KG - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

AiCuris GmbH & Co KG (AiCuris) a subsidiary of Santo Holding AG is a drug development company that discovers and develops antibacterial and antiviral agents for the treatment of life-threatening infectious diseases. The companys pipeline products include antiviral and antibacterial agents for the treatment of severe and life-threatening infectious diseases. It offers drugs for the treatment of human cytomegalovirus, herpes simplex virus, hepatitis B virus and human immunodeficiency virus. The company works in partnership with other drug development companies for the development of medicines targeting human cytomegalovirus. It operates research facility in Wuppertal. AiCuris is headquartered in Wuppertal, Germany.

AiCuris GmbH & Co KG - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 4
List of Figures 4
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Ligand Pharma Enters into Agreement with AiCuris 10
AiCuris Enters Into Drug Discovery Agreement With 4SC Discovery And Crelux 11
Licensing Agreements 13
Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 13
AiCuris GmbH & Co KG - Key Competitors 15
AiCuris GmbH & Co KG - Key Employees 16
AiCuris GmbH & Co KG - Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List Of Tables


AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Key Facts 2
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AiCuris GmbH & Co KG, Deals By Therapy Area, 2012 to YTD 2018 8
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ligand Pharma Enters into Agreement with AiCuris 10
AiCuris Enters Into Drug Discovery Agreement With 4SC Discovery And Crelux 11
Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 13
AiCuris GmbH & Co KG, Key Competitors 15
AiCuris GmbH & Co KG, Key Employees 16

List Of Figures


AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

AiCuris GmbH and Co KG - Pharmaceuticals and Healthcare - Deals and Alliances Profile

AiCuris GmbH & Co KG (AiCuris) a subsidiary of Santo Holding AG is a drug development company that discovers and develops antibacterial and antiviral agents for the treatment of life-threatening

USD 250 View Report

AiCuris GmbH & Co KG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

AiCuris GmbH & Co KG (AiCuris), a subsidiary of Santo Holding AG is a drug development company that discovers and develops antibacterial and antiviral agents for the treatment of life-threatening

USD 250 View Report

Saertex GmbH and Co KG - Strategic SWOT Analysis Review

Saertex GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT

USD 125 View Report

G. Siempelkamp GmbH and Co KG - Strategic SWOT Analysis Review

G. Siempelkamp GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed

USD 125 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available